Dr. Adeel Khan

And it's just, it's just misleading because, and even I thought this, you know, which is that I thought IV stem cells were great, but it turns out a lot of them just get trapped in the lungs and most of them die. And that even with that, you still get some people who get benefits and that's, and that's, and that's the old generation technology, but now we can isolate.

And it's just, it's just misleading because, and even I thought this, you know, which is that I thought IV stem cells were great, but it turns out a lot of them just get trapped in the lungs and most of them die. And that even with that, you still get some people who get benefits and that's, and that's, and that's the old generation technology, but now we can isolate.

We can isolate the best stem cell population and use that one. So it turns out that when you take a stem cell, a mesenchymal stem cell, there's actually 17 subtypes, which is kind of crazy if you think about it. So it's like they, they, there's something called single cell RNA sequencing, which is basically to look at gene expression of individual cell profiles.

We can isolate the best stem cell population and use that one. So it turns out that when you take a stem cell, a mesenchymal stem cell, there's actually 17 subtypes, which is kind of crazy if you think about it. So it's like they, they, there's something called single cell RNA sequencing, which is basically to look at gene expression of individual cell profiles.

So that way you can see how different cells behave. And then you can see that, hey, there's actually these 17 different cliques that they hang out together and they behave differently. And some of them are more useless and some of them are more useful. So we don't necessarily want all 17 subtypes, which is what most stem cell clinics do. And that's what we were doing up until a year ago.

So that way you can see how different cells behave. And then you can see that, hey, there's actually these 17 different cliques that they hang out together and they behave differently. And some of them are more useless and some of them are more useful. So we don't necessarily want all 17 subtypes, which is what most stem cell clinics do. And that's what we were doing up until a year ago.

But as you know, I spent the summer in Japan. And in Japan, they won the Nobel Prize for regenerative medicine, Professor Yamanaka. for cellular reprogramming, and which we can talk about those stem cells. But there was another professor, Professor Mary Dazawa, who discovered something called new cells, which stands for multi lineage, differentiating stress enduring cells. So it's a mouthful.

But as you know, I spent the summer in Japan. And in Japan, they won the Nobel Prize for regenerative medicine, Professor Yamanaka. for cellular reprogramming, and which we can talk about those stem cells. But there was another professor, Professor Mary Dazawa, who discovered something called new cells, which stands for multi lineage, differentiating stress enduring cells. So it's a mouthful.

All you need to remember for people is that these are cells that are used exactly the muse, the muse is a cool stuff. And they're able to, they're pluripotent, which means they can differentiate into all 220 cell types in our body or over 200 cell types. And they are stress enduring, which means they can survive harsh environments. So that's really the key.

All you need to remember for people is that these are cells that are used exactly the muse, the muse is a cool stuff. And they're able to, they're pluripotent, which means they can differentiate into all 220 cell types in our body or over 200 cell types. And they are stress enduring, which means they can survive harsh environments. So that's really the key.

So they don't die when they go in the body. So we can isolate these using cell sorting technology and filter them out so that we're injecting primarily new stem cells instead of just injecting all the different types of stem cells. And so that's now what we've moved on to. And of course, you talked earlier about your back and that's what we use for you.

So they don't die when they go in the body. So we can isolate these using cell sorting technology and filter them out so that we're injecting primarily new stem cells instead of just injecting all the different types of stem cells. And so that's now what we've moved on to. And of course, you talked earlier about your back and that's what we use for you.

And that's what we're using exclusively just because the results are so much more consistent and the science makes a lot of sense. And I'm in the process of doing some clinical work with Professor DeZawa as well. And we want to investigate these new cells for a lot of different conditions, but In Japan, they've already published files for ALS, for heart attacks, for stroke.

And that's what we're using exclusively just because the results are so much more consistent and the science makes a lot of sense. And I'm in the process of doing some clinical work with Professor DeZawa as well. And we want to investigate these new cells for a lot of different conditions, but In Japan, they've already published files for ALS, for heart attacks, for stroke.

And these are not easy to treat conditions. And with intravenous new cells, you do see benefits. And of course, we're seeing that in the real world, treating patients with all sorts of degenerative conditions and actually seeing a real meaningful difference. And that's just because these cells are actually surviving and doing what they are meant to do, which is reduce inflammation and

And these are not easy to treat conditions. And with intravenous new cells, you do see benefits. And of course, we're seeing that in the real world, treating patients with all sorts of degenerative conditions and actually seeing a real meaningful difference. And that's just because these cells are actually surviving and doing what they are meant to do, which is reduce inflammation and

repair cellular function, reduce oxidative stress. We know one of the biggest mechanisms by which they work is through mitochondrial DNA transfer and mitophagy, which is preparing damaged mitochondria. And I think everyone now knows the mitochondria are so important, not just for energy, but for regulating cellular metabolism and aging.

repair cellular function, reduce oxidative stress. We know one of the biggest mechanisms by which they work is through mitochondrial DNA transfer and mitophagy, which is preparing damaged mitochondria. And I think everyone now knows the mitochondria are so important, not just for energy, but for regulating cellular metabolism and aging.

So that's why there's so much interest in this space for longevity and not just orthopedic conditions. And so those are mesenchymal stem cells. And then there's also induced pluripotent stem cells, iPSCs. And that's the Yamanaka stem cells where you can take any old cell and you can make a young again. So, of course, when you think about that, you're like, holy, that's great.

So that's why there's so much interest in this space for longevity and not just orthopedic conditions. And so those are mesenchymal stem cells. And then there's also induced pluripotent stem cells, iPSCs. And that's the Yamanaka stem cells where you can take any old cell and you can make a young again. So, of course, when you think about that, you're like, holy, that's great.